Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease Patients
By Nisreen M. A. Okba, M. Müller, Wentao Li, Chunyan Wang, C. Geurtsvankessel, V. Corman, M. Lamers, Reina S. Sikkema, E. de Bruin, F. Chandler and 9 more. Emerging Infectious Diseases, 2020
1,313 citations recorded by the source corpus.
A new coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has recently emerged to cause a human pandemic. Although molecular diagnostic tests were rapidly developed, serologic assays are still lacking, yet urgently needed. Validated serologic assays are needed for contact tracing, identifying the viral reservoir, and epidemiologic studies. We developed serologic assays for detection of SARS-CoV-2 neutralizing, spike protein–specific, and nucleocapsid-specific antibodies. Using serum samples from patients with PCR-confirmed SARS-CoV-2 infections, other coronaviruses, or other respiratory pathogenic infections, we validated and tested various antigens in different in-house and commercial ELISAs. We demonstrated that most PCR-confirmed SARS-CoV-2–infected persons seroconverted by 2 weeks after disease onset. We found that commercial S1 IgG or IgA ELISAs were of lower specificity, and sensitivity varied between the 2 assays; the IgA ELISA showed higher sensitivity. Overall, the validated assays described can be instrumental for detection of SARS-CoV-2–specific antibodies for diagnostic, seroepidemiologic, and vaccine evaluation studies.
Subfields: Infectious Diseases
View Paper: https://www.semanticscholar.org/paper/7fe8725686925b75ff78468209be07c70f577c4f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Infectious Diseases
Citations in the corpus
- Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual (2020, background): “Although binding and neutralizing antibody responses are known to develop following SARS-CoV-2 infection (Ni et al.; Okba et al., 2020), no information is currently available on the epitope specificities, clonality, binding affinities and neutralizing potentials of the antibody response.”
- Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection (2020, background): “8) and peripheral oxygen saturations <90% (with no history of type 2 respiratory failure (T2RF)) or <85% (with known T2RF) for at least 12 h; (5) Requirement for ECMO.”
- Adaptive immunity to SARS-CoV-2 and COVID-19 (2021, neutral): “anti-Spike cross-neutralizing antibodies are rare (Amanat et al., 2020; Okba et al., 2020; Suthar et al., 2020; Tan et al., 2020b; Wec et al., 2020), as are cross-reactive Spike memory B cells (see above).”